NewAmsterdam Phar…
USUSDNewAmsterdam Pharma Company N.V. Ordinary Shares (US:NAMS) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 1. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- ir.newamsterdampharma.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- NARRDEN, Netherlands
- CEO
- Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Mitarbeiter
- 100
- Ausstehende Aktien
- 119.54 Mio. Stand 2026-08-03
- Streubesitz
- 81.5 Mio.
- Marktkapitalisierung
- 2.89 Mrd. USD
- Insider
- 0.9%
- Institutionelle Anleger
- 106.61%
- Branche (SIC)
- Pharmaceutical Preparations
Beschreibung
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Börsen und Ticker
| Börse | Ticker | Währung | Preis | Typ |
|---|---|---|---|---|
| US USA Stocks | NAMS | USD | 22.8 -1.72% | Stammaktie |
Dividenden
Keine Dividendenzahlungen gefunden (geprüft 06.10.2026). Das Unternehmen schüttet wahrscheinlich keine Dividenden aus.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Frazier Life Sciences Ma… | 15.13% | 18.09 Mio. | 2026-06-30 |
| Capital World Investors | 10.23% | 12.23 Mio. | 2026-06-30 |
| FMR, LLC | 8.65% | 10.34 Mio. | 2026-06-30 |
| RA Capital Management, L… | 7.99% | 9.55 Mio. | 2026-06-30 |
| SmallCap World Fund Inc | 7.75% | 9.27 Mio. | 2026-06-30 |
| FCPM III Services B.V. | 7.1% | 8.49 Mio. | 2026-06-30 |
| Deerfield Management Com… | 3.57% | 4.26 Mio. | 2026-06-30 |
| Viking Global Investors,… | 3.52% | 4.2 Mio. | 2026-06-30 |
| Bain Capital Life Scienc… | 3.18% | 3.81 Mio. | 2026-06-30 |
| Maverick Capital Ltd. | 2.73% | 3.27 Mio. | 2026-06-30 |
| Duquesne Family Office L… | 2.57% | 3.07 Mio. | 2026-06-30 |
| Fidelity Contrafund | 1.95% | 2.33 Mio. | 2026-07-31 |
| Fidelity Rutland Square… | 1.87% | 2.24 Mio. | 2026-07-31 |
| DAVIDSON MICHAEL H (Chie… | ≈0.9% | 1.08 Mio. | 2026-09-14 |
| New Economy Fund | 0.8% | 957 477 | 2026-06-30 |
| T. Rowe Price Health Sci… | 0.76% | 912 500 | 2026-06-30 |
| Fidelity Select Portfoli… | 0.71% | 847 600 | 2026-07-31 |
| -Capital Group U.S. Smal… | 0.51% | 608 660 | 2026-05-31 |
| iShares Trust-iShares Bi… | 0.5% | 603 124 | 2026-08-31 |
| Prudential Sector Funds,… | 0.45% | 534 102 | 2026-05-31 |
| American Century Mutual… | 0.44% | 524 241 | 2026-07-31 |
| SOMAIYA MAYUR IAN (Chief… | ≈0.05% | 58 382 | 2026-01-21 |
| MARINO MICHAEL F III (Of… | ≈0.05% | 55 000 | 2025-05-30 |
| KLING DOUGLAS F (Chief O… | ≈0.04% | 44 000 | 2025-07-16 |
| JONES WILLIAM A JR (Offi… | ≈0.04% | 43 000 | 2025-01-07 |
| KOOIJ LOUISE FREDERIKA (… | ≈0.02% | 24 353 | 2026-07-20 |
| AUDET JULIETTE BERANGERE… | ≈0.01% | 15 104 | 2025-01-07 |
| FORGROWTH NAP B.V. (Bene… | — | — | 2024-12-30 |
| KASTELEIN JOHANNES JACOB… | — | — | 2026-08-24 |
| TOPPER JAMES N (Director… | — | — | 2025-09-15 |
Meldungen an die Aufsicht
| Datum | Aufsichtsbehörde | Ereignis | Details |
|---|---|---|---|
| 2026-10-02 | SEC | інсайдерська подача | Форма 4 |
| 2026-09-29 | SEC | поточний звіт | Форма 8-K |
